Updated

BioMarin shares jumped 5% after the company reached a global patent settlement with Ascendis Pharma, resolving intellectual property disputes between the two biopharmaceutical firms. The settlement removes litigation overhang and provides clarity for BioMarin's product portfolio going forward.